Discovery of potent inhibitors of PLproCoV2 by screening libraries of selenium-containing compounds
E. Weglarz-Tomczak, J. M. Tomczak, M. Giurg, M. Burda-Grabowska, S. Brul
Abstract
A collection of twelve organoselenium compounds, structural analogues of antioxidant drug ebselen were screened for inhibition of the papain-like protease (PLpro) from the acute respiratory syndrome coronavirus 2 (SARS-CoV-2, CoV2). This cysteine protease, being responsible for the hydrolysis of peptide bonds between specific amino acids, plays a critical role in CoV2 replication and in assembly of new viral particles within human cells. The activity of the PLpro CoV2 is essential for the progression of coronavirus disease 2019 (COVID-19) and it constitutes a key target for the development of anti-COVID-19 drugs. Here, we identified four strong inhibitors that bind favorably to the PLpro CoV2 with the IC50 in the nanomolar range.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ebselen as a highly active inhibitor of PLProCoV2
E. Weglarz-Tomczak, J. M. Tomczak, … S. Brul·bioRxiv·May 17, 2020
- Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies
M. Zmudzinski, W. Rut, … M. Drag·bioRxiv·Aug 30, 2020
- Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules
- Drug Repurposing for the SARS-CoV-2 Papain-Like Protease
C.-C. D. Cho, S. G. Li, … W. R. Liu·bioRxiv·Jun 4, 2021
- Mechanism and inhibition of SARS-CoV-2 PLpro
T. Klemm, G. Ebert, … D. Komander·bioRxiv·Jun 18, 2020
- Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures